Report cover image

Alopecia Areata (AA)

Publisher Reach Market Research
Published Jan 01, 2022
Length 27 Pages
SKU # RMR19136481

Description

MarketVue®: Alopecia Areata

The MarketVue®: Alopecia Areata market landscape report combines primary (KOL interviews and survey data) and secondary market research to empower strategic decision-making and provide a complete view of the market.
Every MarketVue® includes a disease overview, epidemiology (US and EU5), current treatment, unmet needs, pipeline and access and reimbursement chapter.

Topics covered in this report:
• Disease overview: Review the disease pathophysiology and potential druggable targets
• Epidemiology: Understand prevalence, diagnosed and drug-treated prevalence of the population and key market segments
• Current treatment: Understand the treatment decision tree and strengths and weaknesses of current on-label and off-label treatment
• Unmet needs: Identify opportunities to address treatment or disease management gaps
• Pipeline analysis: Compare current and emerging therapy clinical development strategy; their performance on efficacy, safety, and delivery metrics; and their potential to address unmet needs
• Value and access: Review the evidence needed to assess and communicate value to key stakeholders (e.g., providers, payers, regulators) and learn what competitors have done or are doing

Methodology:
Research for the MarketVue®: Alopecia Areata report is supported by 6 qualitative interviews with key opinion leaders, a quantitative survey with 25 U.S. physicians and secondary research.

Geographies covered:
United States plus epidemiology for EU5 (France, Germany, Italy, Spain, United Kingdom)

Key companies mentioned:
• Eli Lilly
• Incyte
• Pfizer
• Concert Pharmaceuticals
• AbbVie
• Suzhou Zelgen Biopharmaceuticals
• Legacy Healthcare
• Throne Biotechnologies
• Arena Pharmaceuticals
• Reistone Biopharma
• Bioniz Therapeutics / Equillium

Key drugs mentioned:
• Injectable and topical steroids
• Minoxidil (Rogaine)
• Methotrexate (Trexall, Rheumatrex)
• Diphencyprone (DPCP)
• Tacrolimus (Prograf , Protopic)
• Baricitinib (Olumiant)
• Tofacitinib (Xeljanz)
• Dupilumab (Dupixent)
• Ruxolitinib (Jakafi, Opzelura)
• Adalimumab (Humira)
• Upadacitinib (Rinvoq
• Ritlecitinib (Litfulo)
• Coacillium
• Stem Cell Educator (SCE) therapy
• Etrasimod (Velsipity)
• SHR0302
• BNZ-1
• Jaktinib


Please note: the online download version of this report is for a global site license.

Table of Contents

27 Pages
1. DISEASE OVERVIEW
An autoimmune condition that causes hair to fall out
Table 1.1. Types of alopecia areata
2. EPIDEMIOLOGY & PATIENT POPULATIONS
Disease definition
Figure 2.1. G6 prevalent cases of alopecia areata by region
Table 2.1 Prevalent alopecia areata population in the US and EU5
Patchy alopecia areata is the predominate form of the disease
Figure 2.2. Alopecia areata population by severity
Figure 2.3. Dermatologist-reported key population dynamics in alopecia areata
3. CURRENT TREATMENT
Overview
Figure 3.1. Treatment goals for alopecia areata
Figure 3.2. U.S. dermatologist alopecia areata patient load
Standard of care
Figure 3.3. U.S. Dermatologist-reported patient share of current treatments in alopecia areata
Table 3.1. Upsides and downsides of currently available treatment options
Figure 3.4. Treatment algorithm for the management of alopecia areata
In their own words: Dermatologists’ insights on alopecia areata treatments
Dermatologists hope JAK inhibitors will become the first-approved class for alopecia area
Table 3.2. Must-know alopecia areata treatment dynamics for now and the future
The burden of disease in alopecia areata is not just cosmetic but also psychosocial in nature
Figure 3.5. Dermatologists’ rating of the impact of alopecia areata on patients
In their own words: More of dermatologists’ thoughts on the burden of alopecia areata
Dermatologists are excited about JAK inhibitors but the pipeline is weak for other MOAs
Figure 3.6. Timeline of alopecia areata market evolution
4. UNMET NEED
Overview
Figure 4.1. Top unmet needs in alopecia areata
Figure 4.2. Dermatologist-reported unmet needs in alopecia areata
In their own words: Dermatologists opinion on top unmet needs for alopecia areata
Figure 4.3. Percentage of alopecia areata patients in which U.S. dermatologists are dissatisfied with current therapies
Figure 4.4. U.S. dermatologists view on the need for new treatments in dermatology conditions
Alopecia areata patient insights on unmet needs
Figure 4.5. Key takeaways from the FDA’s “Voice of the Patient” on alopecia areata
5. PIPELINE ANALYSIS
Clinical trials for alopecia areata are focused on promoting scalp hair regrowth
Figure 5.1. Number of emerging therapies addressing unmet needs in alopecia areata
Figure 5.2. Percentage of dermatologists rating target as “promising” for treating alopecia areata
Dermatologists are cautious but not deterred over FDA warning for JAK inhibitors
Summary of clinical-stage emerging alopecia areata therapies
Figure 5.3. Phase 3 results for Eli Lilly/Incyte’s baricitnib in severe alopecia areata
Table 5.1. Emerging alopecia areata therapies
6. VALUE & ACCESS
Overview
Table 6.1. Alopecia areata current therapy pricing, U.S.
Reimbursement for alopecia areata drugs will be met with hurdles
Table 6.2. ICD-10 diagnosis codes for alopecia areata
Figure 6.1. Reimbursement and access considerations for emerging therapies in alopecia areata
Figure 6.1. Alopecia areata patients by insurance type in the U.S.
Figure 6.2. Alopecia areata patients by insurance type in the U.S.
Figure 6.3. Key considerations for building a market access strategy in alopecia areata
7. METHODOLOGY
Primary market research approach
Epidemiology methodology
Disease definition
Prevalence estimates

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us